Other studies also suggested that after resistance to the PD-1/PD-L1 regimen, the following combination regimens using ICIs can continue to provide clinical benefits (19): 1) immunotherapy combined with chemotherapy: 35 patients with advanced NSCLC who underwent immunotherapy were treated with pembrolizumab combined with chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.